Скачать с ютуб Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results в хорошем качестве

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Patients with Relapsed Refractory Multiple Myeloma: Updated Phase 1 Results What is the background of the study? B-cell maturation antigen (BCMA)-targeted immunotherapies are promising treatment options for patients with relapsed/refractory multiple myeloma (MM). Teclistamab (JNJ-64007957) is a bispecific immunoglobulin G4 antibody that binds to both BCMA and CD3 to redirect CD3+ T cells to BCMA-expressing MM cells. In this video: Dr. Neils van de Donk (Amsterdam University Medical Center Amsterdam, Netherlands) discusses the Phase I results of Teclistamab in Patients with Relapsed Refractory Multiple Myeloma. Conclusions: At the RP2D of weekly 1500 μg/kg SC, teclistamab was well-tolerated and demonstrated encouraging efficacy with durable, deepening responses, warranting further investigation as monotherapy and in combination with other agents. With the extended exposure profile at the RP2D and delayed and low-grade CRS observed with SC administration, alternative SC dosing strategies are being explored. _______________ Improving Lives Through Research and Patient Care In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly. Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License